Preventive cholera vaccination resumes as global supply reaches critical milestone

Preventive cholera vaccination resumes as global supply reaches critical milestone

Skip to main content

Oral Cholera vaccination Campaign (OCV), Sannah IDPs camp, Al Dhale'e - 9 December 2024

Preventive cholera vaccination resumes as global supply reaches critical milestone

First preventive campaign in over three years launches in Mozambique, with others planned in Bangladesh and the Democratic Republic of the Congo

Global cholera vaccine supply has now increased to a level sufficient to allow the resumption of life-saving preventive campaigns for the first time in over three years, Gavi, the Vaccine Alliance, UNICEF, and the World Health Organization (WHO) announced today.

Mozambique is the first country to restart preventive vaccination, following the halt in 2022 caused by the global surge in cholera cases that drove up demand and led to shortages of oral cholera vaccine (OCV) stocks.

The preventive vaccination campaign begins amid an ongoing cholera outbreak and the aftermath of floods that affected more than 700 000 people and displaced many. The floods disrupted health systems and damaged water systems, further increasing the risk of waterborne diseases such as cholera.

“Global vaccine shortages forced us into a cycle of reacting to cholera outbreaks instead of preventing them. We are now in a stronger position to break that cycle. I thank EUBiologics, currently the only manufacturer producing cholera vaccines at the scale needed for mass vaccination campaigns, for its efforts, and urge others to enter this vital space. These vaccines will save lives,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General.

A first allocation of 20 million doses is being deployed for preventive campaigns. Of these, 3.6 million doses were delivered to Mozambique; 6.1 million to the Democratic Republic of the Congo that is also experiencing significant outbreaks; and 10.3 million doses are planned for delivery to Bangladesh.

Following sustained efforts by global agencies, manufacturers and partners, annual global supply of OCV has doubled from 35 million doses in 2022 to nearly 70 million doses in 2025. The doses are being financed by Gavi, and procured and delivered to countries by UNICEF.

“The multi-year surge in cholera cases and resulting unprecedented demand for vaccines were stark reminders that sustainable, accessible vaccine supply is a global public good – and the world cannot afford complacency,” said Dr Sania Nishtar, CEO of Gavi, the Vaccine Alliance. “We are grateful to our partners and manufacturers, particularly EUBiologics, for the collaboration that has made the resumption of these essential preventive campaigns possible, and to Gavi’s donors, whose support enables us to finance the global OCV stockpile and life-saving outbreak and preventive campaigns.”

“For the first time in years, this increase in vaccines will allow us to better prevent large-scale cholera emergencies,” said Catherine Russell, UNICEF Executive Director. “Resuming preventive cholera vaccination will protect children and help stop this highly contagious disease in its tracks. But it must go hand in hand with other efforts, including better access to safe water and basic sanitation.”

The three countries were chosen based on allocation criteria set out by the Global Task Force for Cholera Control (GTFCC), a partnership of over 50 organizations, to ensure cholera vaccines for preventive campaigns are distributed systematically, equitably and transparently.

“This milestone shows the power of bringing together diverse partners to build a more reliable response to cholera. Preventive vaccination helps shield communities and buys critical time. However, lasting progress will depend on long‑term investment in infrastructure, for which political commitment is indispensable,” said Dr Ilesh Jani, chair of the Steering Committee of the GTFCC.

The restoration of preventive vaccination has been made possible by years of sustained efforts and close collaboration among agencies, manufacturers, and other partners to meet the continued high demand to respond to outbreaks, expand production capacity and streamline allocation, ensuring that limited s